Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis

BACKGROUND: Therapeutic strategies that induce effective neuroprotection and enhance intrinsic repair mechanisms are central goals for future treatment of multiple sclerosis (MS), as well as other diseases. Laquinimod (LQ) is an orally administered, central nervous system (CNS)-active immunomodulato...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Spencer, Khalaj, Anna J, Yoon, JaeHee, Patel, Rhusheet, Hannsun, Gemmy, Yoo, Timothy, Sasidhar, Manda, Martinez-Torres, Leonardo, Hayardeny, Liat, Tiwari-Woodruff, Seema K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Inc 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868172/
https://www.ncbi.nlm.nih.gov/pubmed/24363970
http://dx.doi.org/10.1002/brb3.174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868172/
https://www.ncbi.nlm.nih.gov/pubmed/24363970
http://dx.doi.org/10.1002/brb3.174

Ejemplares similares